𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chemotherapy as definitive treatment of stage I-II large cell and diffuse mixed lymphomas

✍ Scribed by Fernando Cabanillas


Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
387 KB
Volume
3
Category
Article
ISSN
0278-0232

No coin nor oath required. For personal study only.

✦ Synopsis


Combination chemotherapy with adriamycin-containing regimens is effective in the management of advanced lymphomas. In view of this, we treated 43 patients with clinical stage 1-11 large cell or diffuse mixed lymphoma with chemotherapy. Routine staging laparotomies were not done and radiotherapy was not used in these patients. The CR rate for the combined stage 1-11 presentations is 90%. Of 11 patients with stage 1 presentations, only one has relapsed (at 64 months), and he expired 11 months after the recurrence. Of the 28 patients with stage I1 presentations who achieved a CR, seven have relapsed but three of these have achieved a second CR and remain in remission. Late relapses were common in this group of stage 1-11 presentations. Four of eight relapses occurring in patients who achieved disease-free status took place > 24 months after initiation of therapy. Chemotherapy alone appears to be adequate for treatment of stage I large cell lymphoma, although larger numbers of patients might be required to definitely make this conclusion. Close to 2/3 of patients with stage I1 presentations appear to have been cured with the use of chemotherapy alone. The failures occurred mostly in those with bulky disease. It is possible that radiotherapy given after chemotherapy could consolidate these bulky areas of disease and thus prevent local relapses.


πŸ“œ SIMILAR VOLUMES


Doxorubicin-based chemotherapy for diffu
✍ Keun-Wook Lee; Dae-Young Kim; Tak Yun; Dong-Wan Kim; Tae-You Kim; Sung-Soo Yoon; πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 138 KB πŸ‘ 2 views

## BACKGROUND. Although many studies of elderly patients with non-Hodgkin lymphoma have focused on the dose intensity of chemotherapy, few studies have restricted the histologic inclusion criteria such that only patients with diffuse large B-cell lymphoma (DLCL) are considered. In the current stud

Prognostic value of bcl-6, CD10 and CD38
✍ Maurilio Ponzoni; AndrΓ©s J.M. Ferreri; Giancarlo Pruneri; Barbara Pozzi; Stefani πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 76 KB

## Abstract bcl‐6, CD10 and CD38 are useful markers for identifying 2 molecularly and prognostically distinct profiles of diffuse large B‐cell lymphomas (LCLs), defined as germinal‐center B‐like and activated B‐like. We investigated the prognostic role of bcl‐6, CD10 and CD38 immunoreactivity in 10